The China Extra Corporeal Membrane Oxygenator (ECMO) Interventional landscape, Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future Outlook (2021-2026)
The China Extra Corporeal Membrane Oxygenator (ECMO) report is the first-ever syndicated report that covers the market landscape, procedural and technology trends, and competitive intelligence. The report is based on exhaustive secondary research and in-depth primary research conducted with performing physicians in Interventional Cardiology, Cardiothoracic Surgery, Vascular Surgery, and Pulmonology departments from level 2 and level 3 hospitals in China.
The report covers:
ECMO procedures: veno-arterial and veno-venous
Interventional devices: oxygenators, heparin-coated cannula, ECMO pumps, and gas blenders.
Procedure trends: stages of the disease, ECMO types, performing departments, route of access used for the intervention, and type of interventions
Insights on hospital structure and utilization, physician treatment selection criteria, current and upcoming policies for diagnosis and treatment, and payer coverage are delved into.
Physicians’ brand perception and their rank of medical device companies based on 15 KPIs such as technology, clinical evidence, patient outcome, etc. Moreover, diligent examination of physician’s brand usage and brand satisfaction levels, and the factors such as ease of use of the device, and cost-effectiveness among others effecting brand usage have been covered.
Future trends such as the introduction of the first highly integrated device produced in China that imitates the function of the lungs in cardiopulmonary bypass and uses a novel hemodynamic structure with a spiral flow guide and secondary diversion, as well as a vortex exhaust design to decrease blood cell damage are covered in the report. The report highlights insights about artificial intelligence, deep learning, and machine learning-based algorithms which are being used for augmenting clinical decision-making related to veno-arterial ECMO.
Competitor landscape covers market events such as emerging companies, product approvals, clinical trials, partnerships etc. Competitor activities such as NMPA approval for Xenios AG ECMO Pump by Fresnius Medical and Kewei Membrane oxygenator by MicroPort are covered in the report.
What’s in it for you?
This report will help ECMO treatment device companies understand the ECMO treatment devices landscape, procedural and technology trends, the brand perception, in China.
The report is a great resource to plan your market strategy to capitalize on upcoming trends and potential disruptors in the ECMO treatment devices market.
The deliverable includes a 100+ slide MS PowerPoint report and an MS Excel-based 5-Year market forecast model. REPORT COST: 5,000 USD Contact us below for further details regarding the exclusive data and insights in the report or for an exploratory analyst walkthrough of the report.